vs
Apellis Pharmaceuticals, Inc.（APLS）与GENCO SHIPPING & TRADING LTD（GNK）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是GENCO SHIPPING & TRADING LTD的1.7倍（$199.9M vs $114.4M），GENCO SHIPPING & TRADING LTD净利率更高（8.4% vs -29.5%，领先37.9%），GENCO SHIPPING & TRADING LTD同比增速更快（60.6% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
GENCO航运贸易有限公司是一家国际干散货航运企业，运营多元化散货船船队，主要承运铁矿石、煤炭、粮食、钢材等大宗商品，航线覆盖全球主要贸易通道，服务工业制造、大宗商品交易领域的全球客户。
APLS vs GNK — 直观对比
营收规模更大
APLS
是对方的1.7倍
$114.4M
营收增速更快
GNK
高出66.5%
-5.9%
净利率更高
GNK
高出37.9%
-29.5%
两年增速更快
APLS
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $114.4M |
| 净利润 | $-59.0M | $9.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 11.6% |
| 净利率 | -29.5% | 8.4% |
| 营收同比 | -5.9% | 60.6% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGNK
| Q1 26 | — | $114.4M | ||
| Q4 25 | $199.9M | $109.9M | ||
| Q3 25 | $458.6M | $79.9M | ||
| Q2 25 | $178.5M | $80.9M | ||
| Q1 25 | $166.8M | $71.3M | ||
| Q4 24 | $212.5M | $99.2M | ||
| Q3 24 | $196.8M | $99.3M | ||
| Q2 24 | $199.7M | $107.0M |
净利润APLSGNK
| Q1 26 | — | $9.6M | ||
| Q4 25 | $-59.0M | $15.4M | ||
| Q3 25 | $215.7M | $-1.1M | ||
| Q2 25 | $-42.2M | $-6.8M | ||
| Q1 25 | $-92.2M | $-11.9M | ||
| Q4 24 | $-36.4M | $12.7M | ||
| Q3 24 | $-57.4M | $21.5M | ||
| Q2 24 | $-37.7M | $23.5M |
营业利润率APLSGNK
| Q1 26 | — | 11.6% | ||
| Q4 25 | -25.6% | 17.3% | ||
| Q3 25 | 48.7% | 3.1% | ||
| Q2 25 | -18.6% | -5.3% | ||
| Q1 25 | -50.0% | -13.7% | ||
| Q4 24 | -12.3% | 14.7% | ||
| Q3 24 | -24.0% | 24.2% | ||
| Q2 24 | -14.7% | 24.6% |
净利率APLSGNK
| Q1 26 | — | 8.4% | ||
| Q4 25 | -29.5% | 14.0% | ||
| Q3 25 | 47.0% | -1.3% | ||
| Q2 25 | -23.6% | -8.4% | ||
| Q1 25 | -55.3% | -16.7% | ||
| Q4 24 | -17.1% | 12.8% | ||
| Q3 24 | -29.2% | 21.6% | ||
| Q2 24 | -18.9% | 21.9% |
每股收益（稀释后）APLSGNK
| Q1 26 | — | $0.21 | ||
| Q4 25 | $-0.40 | $0.36 | ||
| Q3 25 | $1.67 | $-0.02 | ||
| Q2 25 | $-0.33 | $-0.16 | ||
| Q1 25 | $-0.74 | $-0.28 | ||
| Q4 24 | $-0.30 | $0.29 | ||
| Q3 24 | $-0.46 | $0.49 | ||
| Q2 24 | $-0.30 | $0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $54.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $887.0M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSGNK
| Q1 26 | — | $54.8M | ||
| Q4 25 | $466.2M | $55.5M | ||
| Q3 25 | $479.2M | $90.0M | ||
| Q2 25 | $370.0M | $35.4M | ||
| Q1 25 | $358.4M | $30.2M | ||
| Q4 24 | $411.3M | $43.7M | ||
| Q3 24 | $396.9M | $46.7M | ||
| Q2 24 | $360.1M | $42.0M |
股东权益APLSGNK
| Q1 26 | — | $887.0M | ||
| Q4 25 | $370.1M | $896.5M | ||
| Q3 25 | $401.2M | $885.9M | ||
| Q2 25 | $156.3M | $891.6M | ||
| Q1 25 | $164.2M | $903.2M | ||
| Q4 24 | $228.5M | $926.7M | ||
| Q3 24 | $237.1M | $929.9M | ||
| Q2 24 | $264.3M | $921.8M |
总资产APLSGNK
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.0B | ||
| Q1 25 | $807.3M | $1.0B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $15.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.64× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSGNK
| Q1 26 | — | $15.7M | ||
| Q4 25 | $-14.2M | $15.9M | ||
| Q3 25 | $108.5M | $7.7M | ||
| Q2 25 | $4.4M | $5.4M | ||
| Q1 25 | $-53.4M | $2.9M | ||
| Q4 24 | $19.4M | $30.0M | ||
| Q3 24 | $34.1M | $35.6M | ||
| Q2 24 | $-8.3M | $29.0M |
自由现金流APLSGNK
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $15.6M | ||
| Q3 25 | $108.3M | $6.5M | ||
| Q2 25 | $4.4M | $4.3M | ||
| Q1 25 | $-53.4M | $2.3M | ||
| Q4 24 | $19.3M | $29.3M | ||
| Q3 24 | — | $34.7M | ||
| Q2 24 | $-8.4M | $27.9M |
自由现金流率APLSGNK
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 14.2% | ||
| Q3 25 | 23.6% | 8.2% | ||
| Q2 25 | 2.5% | 5.3% | ||
| Q1 25 | -32.0% | 3.2% | ||
| Q4 24 | 9.1% | 29.5% | ||
| Q3 24 | — | 34.9% | ||
| Q2 24 | -4.2% | 26.1% |
资本支出强度APLSGNK
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 1.1% |
现金转化率APLSGNK
| Q1 26 | — | 1.64× | ||
| Q4 25 | — | 1.03× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.37× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GNK
暂无分部数据
